Wall Street brokerages expect that Heska Corp (NASDAQ:HSKA) will report sales of $39.62 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heska’s earnings, with estimates ranging from $37.86 million to $41.38 million. Heska posted sales of $39.54 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.2%. The firm is scheduled to report its next quarterly earnings report before the market opens on Wednesday, February 28th.
On average, analysts expect that Heska will report full-year sales of $39.62 million for the current year, with estimates ranging from $134.00 million to $138.00 million. For the next fiscal year, analysts expect that the company will post sales of $151.06 million per share, with estimates ranging from $145.08 million to $155.21 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Heska.
Several equities research analysts recently commented on the stock. B. Riley restated a “hold” rating and issued a $96.50 price target on shares of Heska in a research report on Friday, October 27th. Raymond James Financial reiterated a “buy” rating on shares of Heska in a research report on Monday, December 4th. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Aegis reiterated a “buy” rating on shares of Heska in a research report on Tuesday, December 19th. Finally, Zacks Investment Research downgraded shares of Heska from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $110.08.
In other news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total transaction of $681,957.64. Following the transaction, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 14.70% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its stake in Heska by 6.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,112 shares of the medical research company’s stock valued at $522,000 after buying an additional 294 shares during the last quarter. Voya Investment Management LLC grew its stake in Heska by 15.2% in the 2nd quarter. Voya Investment Management LLC now owns 3,002 shares of the medical research company’s stock valued at $306,000 after buying an additional 395 shares during the last quarter. Royal Bank of Canada grew its stake in Heska by 96.9% in the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock valued at $103,000 after buying an additional 499 shares during the last quarter. New York State Common Retirement Fund grew its stake in Heska by 5.8% in the 2nd quarter. New York State Common Retirement Fund now owns 9,597 shares of the medical research company’s stock valued at $980,000 after buying an additional 525 shares during the last quarter. Finally, Raymond James Trust N.A. grew its stake in Heska by 6.5% in the 3rd quarter. Raymond James Trust N.A. now owns 8,953 shares of the medical research company’s stock valued at $789,000 after buying an additional 543 shares during the last quarter. Institutional investors and hedge funds own 80.03% of the company’s stock.
Shares of Heska (NASDAQ:HSKA) traded up $1.75 during trading hours on Friday, hitting $60.11. 402,272 shares of the company traded hands, compared to its average volume of 88,260. The stock has a market cap of $420.48, a P/E ratio of 30.72, a PEG ratio of 1.57 and a beta of 0.67. Heska has a fifty-two week low of $56.59 and a fifty-two week high of $115.00.
TRADEMARK VIOLATION WARNING: “$39.62 Million in Sales Expected for Heska Corp (HSKA) This Quarter” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/39-62-million-in-sales-expected-for-heska-corp-hska-this-quarter.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Get a free copy of the Zacks research report on Heska (HSKA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.